Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $595.42K, compared with $0 a year earlier.
Context
- Short-term debt amounted to 5.5% of total assets at the end of Q1 FY2026, up 5.5 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 69.07K USD
- Year-over-year change
- —
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 69.07K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Debt vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 short-term debt of $595.42K is the lowest of the 2 companies compared; the peer median is $6.15M.
- Short-term debt amounts to 5.5% of total assets for LIXT, versus a peer median of 19.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.15M | +49.0% | +8.0% | 19.9% | |
| Mar 2026 | $595.42K | — | — | 5.5% | |
| Peer median (excluding LIXT) | $6.15M | +49.0% | +8.0% | 19.9% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.